Chrysosplenol D

CAS No. 14965-20-9

Chrysosplenol D( —— )

Catalog No. M29115 CAS No. 14965-20-9

Chrysosplenol D, an efflux pump inhibitor that can potentiate the activity of commercially important antibiotics and antimalarials.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 237 Get Quote
10MG 372 Get Quote
25MG 608 Get Quote
50MG 849 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Chrysosplenol D
  • Note
    Research use only, not for human use.
  • Brief Description
    Chrysosplenol D, an efflux pump inhibitor that can potentiate the activity of commercially important antibiotics and antimalarials.
  • Description
    Chrysosplenol D, an efflux pump inhibitor that can potentiate the activity of commercially important antibiotics and antimalarials.(In Vitro):Trace amounts of the antimalarial sesquiterpene lactone artemisinin may account for the activity of the n-hexane fraction but only the methoxylated flavonoids artemetin, chrysoplenetin, Chrysosplenol D and cirsilineol can account for the activity of the chloroform extract. These purified flavonoids were found to have IC50 values at 2.4 - 6.5 x 10(-5)M against P. falciparum in vitro compared with an IC50 value of about 3 x 10(-8)M for purified artimisinin. Chrysosplenol D inhibited the viability of the MDA-MB-231 TNBC cells after 48 h with IC50 values of 11.6 μM. The most sensitive cell line towards Chrysosplenol D was the non-small-cell lung carcinoma (NSCLC) cell line A549 and the most resistant one was the androgen-independent prostate carcinoma cell line PC-3. The hormone-sensitive breast cancer cells MCF7 exhibited high resistance towards Chrysosplenol D treatment.(In Vivo):In mice, administration of Chrysosplenol D (1 and 1.5μmol/cm^2) inhibited croton oil-induced ear edema (37.76-65.89%, all P<0.05) in a manner similar to indomethacin (0.5, 1 and 1.5μmol/cm^2; 55.63-84.58%). Chrysosplenol D (0.07, 0.14 and 0.28mmol/kg) protected against LPS-induced systemic inflammatory response syndrome (SIRS) in mice (all P<0.05), in a manner similar to dexamethasone (0.03mmol/kg). Chrysosplenol D suppressed LPS-induced release of IL-1 beta, IL-6 and MCP-1, inhibited cell migration, and reduced LPS-induced IκB and c-JUN phosphorylation in Raw264.7 cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    14965-20-9
  • Formula Weight
    360.318
  • Molecular Formula
    C18H16O8
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (138.77 mM)
  • SMILES
    COc1cc2oc(-c3ccc(O)c(O)c3)c(OC)c(=O)c2c(O)c1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Anakinra

    Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.

  • Siltuximab

    Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.

  • Vunakizumab

    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .